Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2016

22.09.2016 | Correspondence

Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2

verfasst von: Cathy Bennett, Janusz Jankowski, Paul Moayyedi, On behalf of the International BAD CAT and BOB CAT consortia

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the article by Feuerstein et al. “Systematic analysis and critical appraisal quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus” [8]. We note the omission of our international consensus guidelines on management of Barrett’s esophagus [1, 2] from this appraisal. While our recent guideline on the management of non-dysplastic and low-grade dysplasia in Barrett’s osophagus “BOB CAT” [2] is outside the date limits of their search for evidence, our 2012 guideline “BAD CAT” [1] should have been retrieved. This guideline was funded and endorsed by numerous international societies, and the resulting publication is highly cited and accredited by NICE (UK) [3]. BAD CAT [1] involved an international panel of 92 authors, and 11,000 articles were assessed on the management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma. Since the management of Barrett’s with dysplasia was not explicitly excluded from the review, it appears that there is no rationale for the exclusion of the BAD CAT guideline. Had our guideline been included, the authors would have noted that we addressed many of the problems and shortcomings identified by their review of other guidelines, using the AGREE II instrument. Specifically, we assessed both the quality of the scientific evidence included in the review using GRADE [4] and reported conflict of interest declarations in detail. The guideline production method was inclusive, with input from all areas of clinical specialty and patient groups; there was consideration of adverse events and harms; it was peer-reviewed prior to publication, and we identified areas which were directly applicable to clinical management. As an evidence-based consensus group, we sought to maintain editorial independence and collected information about conflict of interest. Any participants who did not provide a conflict of interest statement were excluded from authorship, to ensure the impartiality of the process. …
Literatur
1.
Zurück zum Zitat Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMed Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.CrossRefPubMed
2.
Zurück zum Zitat Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:662–682 (quiz 683).CrossRefPubMedPubMedCentral Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:662–682 (quiz 683).CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.CrossRefPubMed Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–394.CrossRefPubMed
5.
Zurück zum Zitat Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.CrossRefPubMed Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.CrossRefPubMed
6.
Zurück zum Zitat Old O, Moayyedi P, Love S, et al. Barrett’s oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen. 2015;22:158–164.CrossRefPubMed Old O, Moayyedi P, Love S, et al. Barrett’s oesophagus surveillance versus endoscopy at need study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen. 2015;22:158–164.CrossRefPubMed
7.
Zurück zum Zitat Bennett C, Moayyedi P, Corley DA, et al. Addendum: BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:943.CrossRefPubMed Bennett C, Moayyedi P, Corley DA, et al. Addendum: BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol. 2015;110:943.CrossRefPubMed
8.
Zurück zum Zitat Feuerstein JD, Castillo NE, Akbari M, et al. Systematic analysis and critical appraisal of the quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus. Dig Dis Sci. 2016;61:2812–2822.CrossRefPubMed Feuerstein JD, Castillo NE, Akbari M, et al. Systematic analysis and critical appraisal of the quality of the scientific evidence and conflicts of interest in practice guidelines (2005–2013) for Barrett’s esophagus. Dig Dis Sci. 2016;61:2812–2822.CrossRefPubMed
Metadaten
Titel
Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2
verfasst von
Cathy Bennett
Janusz Jankowski
Paul Moayyedi
On behalf of the International BAD CAT and BOB CAT consortia
Publikationsdatum
22.09.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4279-y

Weitere Artikel der Ausgabe 11/2016

Digestive Diseases and Sciences 11/2016 Zur Ausgabe

Stanford Multidisciplinary Seminars

Recurrent Pyogenic Cholangitis: Got Stones?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.